EHA 2026: Long-Term Zanubrutinib Outcomes

Review long-term safety and efficacy data from the SEQUOIA trial evaluating zanubrutinib in treatment-naïve patients aged ≥80 years with CLL/SLL.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free